Related Experiment Video
Updated: Aug 22, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation
Anastasios Apostolos1,2, Vasileios Panoulas1,2
1Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Insights
Triple antithrombotic treatment (TAT) does not reduce left ventricular thrombus (LVT) formation in anterior ST-elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (pPCI). TAT significantly increases major bleeding risk, questioning its routine prophylactic use.
Area of Science:
- Cardiology
- Interventional Cardiology
- Thrombosis Research
Background:
- Left ventricular thrombus (LVT) is a significant complication following anterior ST-elevation myocardial infarction (STEMI).
- Prophylactic anticoagulation is recommended for high-risk patients, but evidence quality is low.
- Primary percutaneous coronary intervention (pPCI) is the standard reperfusion therapy for STEMI.
Purpose of the Study:
- To evaluate the efficacy and safety of triple antithrombotic treatment (TAT) compared to dual antiplatelet therapy (DAPT) alone for LVT prevention.
- To assess the impact of TAT on LVT formation, major bleeding, and systemic embolism in anterior STEMI patients undergoing pPCI.
Main Methods:
- Systematic review and meta-analysis of six studies involving 2,021 patients.
- Searched EMBASE, MEDLINE, and Cochrane Library databases following PRISMA 2020 guidelines.
- Pooled data using random-effects models to calculate risk ratios (RR) and 95% confidence intervals (CI).
Main Results:
- Triple antithrombotic treatment (TAT) did not significantly reduce left ventricular thrombus (LVT) formation (RR 0.54, p=0.21).
- TAT significantly increased the risk of major bleeding (RR 2.69, p=0.003).
- A non-significant trend towards reduced systemic embolism was observed with TAT (RR 0.44, p=0.07).
Conclusions:
- Prophylactic TAT in anterior STEMI patients treated with pPCI does not significantly decrease LVT formation.
- The increased risk of major bleeding associated with TAT outweighs potential benefits in unselected patients.
- Routine prophylactic TAT is not supported for unselected anterior STEMI patients undergoing pPCI.
Abstract:
Left ventricular thrombus (LVT) is a serious complication of anterior ST-elevation myocardial infarction (STEMI). Despite guideline endorsement of prophylactic anticoagulation in selected high-risk patients, the supporting evidence remains of low certainty. Aim of our systematic review and meta-analysis is to evaluate the efficacy and safety of triple antithrombotic treatment (TAT) versus dual antiplatelet treatment (DAPT) alone for LVT prevention in patients with anterior STEMI treated with primary percutaneous coronary intervention (pPCI). Three electronic databases (EMBASE, MEDLINE, Cochrane Library) were systematically searched from inception to February 2026, following PRISMA 2020 guidelines. Eligible studies enrolled adult patients with anterior STEMI revascularised by pPCI, compared prophylactic TAT with DAPT alone, and reported LVT outcomes. Data were pooled as risk ratios (RR) with 95% confidence intervals (CI) using random-effects models. The primary outcome was LVT formation; secondary outcomes were major bleeding and systemic embolism. Six studies including 2,021 patients were analyzed. Pooled analysis demonstrated no statistically significant reduction in LVT formation with TAT (RR 0.54, 95% CI 0.21-1.40; p=0.21; I2=61%), whereas major bleeding risk was significantly increased (RR 2.69, 95% CI 1.40-5.19; p=0.003; I2=14%). A non-significant trend toward reduced systemic embolism was observed (RR 0.44, 95% CI 0.18-1.07; p=0.07; I2=0%). The addition of prophylactic anticoagulation to DAPT in patients with anterior STEMI treated with pPCI does not show a statistically significant reduction in LVT formation while significantly increasing major bleeding risk. These findings do not support routine prophylactic TAT in unselected patients with anterior STEMI.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Mitral Stenosis III: Medical Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Aortic Regurgitation III: Medical Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cardiac Catheterization III: Left Heart Catheterization